glp-1 weight loss drug news today 2025 Targeted Peptide Drugs Market Size to Reach USD 193.44 Billion by 2034 New oral GLP-1 drugs could

Liu J, Li L, Li S, et al

Petta S, Kim K, Targher G, et al

Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease

SAXENDAKey Asset in Novo Nordisk Obesity Market Novo Nordisk weight loss drug, SAXENDA (liraglutide), is a GLP-1 receptor agonist designed to support long-term weight loss when combined with a reduced-calorie diet and increased physical activity

Furthermore, there was a significant reduction of CRP level with semaglutide ( 43.5% vs 7.3% with placebo, estimated treatment ratio, 0.61

Both acute and 4-hour exposure to GLP-1 slowed gastric emptying markedly, but the degree of deceleration was less for the second meal